Invention Grant
- Patent Title: Anti-CXCR4 antibodies and their use for the treatment of cancer
- Patent Title (中): 抗CXCR4抗体及其用于治疗癌症的用途
-
Application No.: US14025875Application Date: 2013-09-13
-
Publication No.: US09388248B2Publication Date: 2016-07-12
- Inventor: Christine Klinguer-Hamour , Alexandra Jouhanneaud , Veronique Grenier-Caussanel
- Applicant: PIERRE FABRE MEDICAMENT
- Applicant Address: FR Boulogne-Billancourt
- Assignee: Pierre Fabre Medicament
- Current Assignee: Pierre Fabre Medicament
- Current Assignee Address: FR Boulogne-Billancourt
- Agency: Finnegan, Henderson, Farabow, Garrett and Dunner, L.L.P.
- Priority: EP08305631 20081001
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C12P21/08 ; C07K16/30 ; C07K16/28 ; A61K39/395 ; A61K45/06
Abstract:
The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to the 414H5 and 515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered.
Public/Granted literature
- US20140050661A1 NOVEL ANTI-CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER Public/Granted day:2014-02-20
Information query
